Patents by Inventor Michael P. Murphy

Michael P. Murphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130064768
    Abstract: The present invention provides an imaging probe which comprises a lipophilic cation, a hydrophobic moiety and a PET nucleus. The present invention also provides a precursor molecule for the production of such an imaging probe and methods for using the probe for analysing mitochondrial membrane potential in a subject.
    Type: Application
    Filed: March 24, 2011
    Publication date: March 14, 2013
    Applicants: Medical Research Council, University of Otago, Cambridge Enterprise Limited
    Inventors: David K. Menon, Michael P. Murphy, Franklin I. Aigbirhio, Robin A. Smith
  • Publication number: 20120273053
    Abstract: An ER fluid valve includes a housing and a plurality of parallel flow passages through the housing each defined by spaced electrodes at least one of which is controllable independently of other flow passages electrodes. A controller is configured to selectively establish electrical fields for all of the independently controllable electrodes to close all of the flow passages to ER fluid flowing through the housing. By removing the fields from all of the independently controllable electrodes, all the flow passages are open to the ER fluid flowing through the housing. By establishing fields for select independently controllable electrodes to close their associated flow passages and by leaving other flow passages open, restricted flow of the ER fluid through the housing is accomplished to vary the flow rate through the housing.
    Type: Application
    Filed: April 27, 2011
    Publication date: November 1, 2012
    Inventors: Michael P. Murphy, Robert Playter
  • Publication number: 20120258083
    Abstract: The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the invention may function as endothelial precursors and may provide therapeutic preparations, for example, in the treatment of ischemia.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Inventor: Michael P. Murphy
  • Publication number: 20120037533
    Abstract: A suspended utensil storage system includes a utensil tray including a plurality of utensil compartments having a mesh material therein; and a debris collector tray underlying the utensil tray and receiving the utensil tray. The mesh material of the utensil compartments of the utensil tray supports utensils and includes holes sized to allow debris to fall there through into the debris collector tray for collecting the debris.
    Type: Application
    Filed: October 26, 2011
    Publication date: February 16, 2012
    Inventor: Michael P. Murphy
  • Patent number: 8047373
    Abstract: A suspended utensil storage system includes a utensil tray including a plurality of utensil compartments having a mesh material therein; and a debris collector tray underlying the utensil tray and receiving the utensil tray. The mesh material of the utensil compartments of the utensil tray supports utensils and includes holes sized to allow debris to fall there through into the debris collector tray for collecting the debris.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: November 1, 2011
    Inventor: Michael P. Murphy
  • Patent number: 7966734
    Abstract: A tack strip cutter including a top blade holder and a bottom blade holder having a leverage handle for bringing the blade holders together with a leverage force. A splay inhibition guide on one of the blade holders prevents lateral movement of the blade holders when the tool is used.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: June 28, 2011
    Assignee: Crain Cutter Company, Inc.
    Inventors: Lance D. Crain, Michael P. Murphy
  • Publication number: 20110097713
    Abstract: Compositions and methods for determining an optimal dose of a medication for a subject are described that include determining the subject's genotype for the CYP2C9 and VKORC1 genes and determining the dose of the medication based on the genotype. Articles of manufacture also are provided that include polynucleotides for genotyping.
    Type: Application
    Filed: August 21, 2009
    Publication date: April 28, 2011
    Inventors: Thomas Briggs, James R. Johnson, Jeremy C. Pridgen, Michael P. Murphy, Suzanne L. Phillips, Pamela J. Nakhle
  • Publication number: 20100282635
    Abstract: A suspended utensil storage system includes a utensil tray including a plurality of utensil compartments having a mesh material therein; and a debris collector tray underlying the utensil tray and receiving the utensil tray. The mesh material of the utensil compartments of the utensil tray supports utensils and includes holes sized to allow debris to fall there through into the debris collector tray for collecting the debris.
    Type: Application
    Filed: May 3, 2010
    Publication date: November 11, 2010
    Inventor: Michael P. Murphy
  • Patent number: 7824913
    Abstract: Cultured tissue constructs comprising cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have morphological features and functions similar to tissues their cells are derived and their strength makes them easily handleable. Preferred cultured tissue constructs of the invention are prepared in defined media, that is, without the addition of chemically undefined components.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: November 2, 2010
    Assignee: Organogenesis, Inc.
    Inventors: Michael P. Murphy, Vincent Ronfard
  • Publication number: 20100137426
    Abstract: Reference controls for use with pharmacogenomic testing, and methods for their identification, preparation, and use, are disclosed. The reference controls can confirm that pharmacogenomic testing correctly identifies individuals that do or do not have the mutation of interest, in both clinical trial and patient treatment settings. The reference controls can be selected to include one or more mutations to be identified, and prescreened to confirm that they bind to one or more of the primers used in the pharmacogenomic testing. The reference controls are human genomic DNA that includes certain identified polymorphisms (mutations) of interest, ideally derived from individuals, pre-selected and optionally properly consented, which have one or more of the polymorphism(s) of interest.
    Type: Application
    Filed: May 1, 2009
    Publication date: June 3, 2010
    Applicant: PARAGON
    Inventors: Michael P. Murphy, L. Scott Clark, Pamela J. Nakhle, Kenneth G. Butz
  • Publication number: 20090197945
    Abstract: Reference controls for use with pharmacogenomic testing, and methods for their identification, preparation, and use, are disclosed. The reference controls can confirm that pharmacogenomic testing correctly identifies individuals that do or do not have the mutation of interest, in both clinical trial and patient treatment settings. The reference controls can be selected to include one or more mutations to be identified, and prescreened to confirm that they bind to one or more of the primers used in the pharmacogenomic testing. The reference controls are human genomic DNA that includes certain identified polymorphisms (mutations) of interest, ideally derived from individuals, pre-selected and optionally properly consented, which have one or more of the polymorphism(s) of interest.
    Type: Application
    Filed: January 29, 2007
    Publication date: August 6, 2009
    Inventors: Michael P. Murphy, Scott L. Clark, Pamela J. Nakhle, Kenneth G. Butz
  • Publication number: 20090186006
    Abstract: The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the invention may function as endothelial precursors and may provide therapeutic preparations, for example, in the treatment of ischemia.
    Type: Application
    Filed: January 16, 2009
    Publication date: July 23, 2009
    Inventor: Michael P. Murphy
  • Publication number: 20080275005
    Abstract: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR.Z- where X is a linking group, Z is an anion and R is an antioxidant moiety. Also provided are pharmaceutical compositions containing the mitochondrially targeted antioxidant compounds, and methods of therapy or prophylaxis of patients who would benefit from reduced oxidative stress, which comprise the step of administering the compounds of the invention.
    Type: Application
    Filed: April 24, 2008
    Publication date: November 6, 2008
    Inventors: Michael P. Murphy, Robin A.J. Smith
  • Patent number: 7232809
    Abstract: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR.Z? where X is a linking group, Z is an anion and R is an antioxidant moiety. Also provided are pharmaceutical compositions containing the mitochondrially targeted antioxidant compounds, and methods of therapy or prophylaxis of patients who would benefit from reduced oxidative stress, which comprise the step of administering the compounds of the invention.
    Type: Grant
    Filed: July 5, 2005
    Date of Patent: June 19, 2007
    Assignee: Antipodean Pharmaceuticals, Inc.
    Inventors: Michael P. Murphy, Robin A. J. Smith
  • Patent number: 7109189
    Abstract: The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: September 19, 2006
    Assignees: University of Otago, Medical Research Council
    Inventors: Michael P. Murphy, Robin A. J. Smith
  • Patent number: 6984636
    Abstract: The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to an antioxidant moiety which is either a superoxide dismutase (SOD) mimetic or a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: January 10, 2006
    Assignees: Medical Research Council, University of Otago
    Inventors: Michael P. Murphy, Robin A. J. Smith
  • Publication number: 20040106579
    Abstract: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR.Z- where X is a linking group, Z is an anion and R is an antioxidant moiety. Also provided are pharmaceutical compositions containing the mitochondrially targeted antioxidant compounds, and methods of therapy or prophylaxis of patients who would benefit from reduced oxidative stress, which comprise the step of administering the compounds of the invention.
    Type: Application
    Filed: November 28, 2003
    Publication date: June 3, 2004
    Applicant: University of Otago
    Inventors: Michael P. Murphy, Robin A.J. Smith
  • Publication number: 20040029851
    Abstract: The invention provides mitochondrially targeted antioxidant compounds comprising a lipophilic cation moiety covalently coupled to an antioxidant moiety which is either a superoxide dismutase (SOD) mimetic or a glutathione peroxidase mimetic. These compounds can be used to treat patients who would benefit from the reduction of oxidative stress.
    Type: Application
    Filed: August 12, 2002
    Publication date: February 12, 2004
    Applicants: Medical Research Council, University of Otago
    Inventors: Michael P. Murphy, Robin A.J. Smith
  • Patent number: D628381
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: December 7, 2010
    Assignee: Omnimount Systems, Inc.
    Inventors: Michael P. Murphy, Zachary I. Eyman
  • Patent number: D667278
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: September 18, 2012
    Inventor: Michael P. Murphy